Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02537522 · ClinicalTrials.gov registry record · Phase 4

Evaluation of 8.5 vs 9.0 Base Curve for 1-DAY ACUVUE(r) TruEye(r) Brand Contact Lenses

A Phase 4 study, sponsored by Johnson & Johnson Vision Care.

Completed
Registry status
Phase 4
Development phase
72
Enrollment target

NCT02537522: Completed Phase 4 study, sponsored by Johnson & Johnson Vision Care.

NCT02537522 is a Phase 4 study that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 72 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02537522, a Phase 4 study, has completed, sponsored by Johnson & Johnson Vision Care.

COMPLETED
Registry status
Phase 4
Development phase
72 participants
Enrollment target

Study Summary

The objective of this study is to determine if corneal diameter and keratometry readings correlate to subjective comfort and lens fitting characteristics.

Primary Outcome

CLUE- The Contact Lens User Evaluation (CLUE)™ questionnaire is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20) with a range of 0-120, where higher scores indicate a more favorable/positive

Interventions

  • DEVICE Contact Lenses with 8.5 BC
  • DEVICE Contact Lenses with 9.0 BC

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2015-07-01
Est. Completion 2015-07-01
Phase Phase 4
Johnson & Johnson Vision Care

142 total trials

What the finished NCT02537522 record still lists

NCT02537522 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).

The record links to 0 conditions, and to 2 interventions - of which Contact Lenses with 8.5 BC is the first listed.

NCT02537522 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02537522 about?

NCT02537522 is a clinical study titled "Evaluation of 8.5 vs 9.0 Base Curve for 1-DAY ACUVUE(r) TruEye(r) Brand Contact Lenses". The objective of this study is to determine if corneal diameter and keratometry readings correlate to subjective comfort and lens fitting characteristics.

What is the current status of trial NCT02537522?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2015-07-01. Estimated completion is 2015-07-01.

What interventions are being tested in trial NCT02537522?

The interventions under investigation include: Contact Lenses with 8.5 BC (DEVICE), Contact Lenses with 9.0 BC (DEVICE).

Who is sponsoring clinical trial NCT02537522?

This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02537522's enrollment target sits among peer trials

72 1035th of 2000 higher than 961 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02537522, the US trial registry maintained by the National Library of Medicine. NCT02537522 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.